Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Ruben R. Plentz

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5103338850. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
32
Papers, trials and grants by year

2014: 3 papers · 2015: 1 paper · 2016: 1 paper · 2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 2 papers

Papers 8

  1. Predictive criteria for overall survival and treatment duration of 2nd-line chemotherapy in patients with advanced pancreatic adenocarcinoma (AIO-PAK-0216). Co-author DOI 10.1038/s41416-025-03188-x↗
  2. Body mass index has no impact on complications and mortality for patients with stage IV pancreatic ductal adenocarcinoma. Last author DOI 10.21037/tgh-2025-160↗
  3. Therapeutic effects of Argyrin F in pancreatic adenocarcinoma. Last author DOI 10.1016/j.canlet.2017.04.003↗
  4. Urinary Peptide Analysis Differentiates Pancreatic Cancer From Chronic Pancreatitis. Co-author DOI 10.1097/mpa.0000000000000573↗
  5. Patients with Advanced Pancreatic Cancer and Hyperbilirubinaemia: Review and German Expert Opinion on Treatment with nab-Paclitaxel plus Gemcitabine. Co-author DOI 10.1159/000441310↗
  6. DCLK1 marks a morphologically distinct subpopulation of cells with stem cell properties in preinvasive pancreatic cancer. Co-author DOI 10.1053/j.gastro.2013.09.050↗
  7. Combined inhibition of Notch and JAK/STAT is superior to monotherapies and impairs pancreatic cancer progression. Last author DOI 10.1093/carcin/bgt394↗
  8. Analysis of second-line chemotherapies for ductal pancreatic adenocarcinoma in a German single-center cohort. Last author DOI 10.3109/00365521.2014.978816↗

Closest collaborators

The 25 strongest of 32 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ren Bryant · 1 shared paper, 2026 · strength 0.36
  2. Thomas Jens Ettrich · 1 shared paper, 2026 · strength 0.22
  3. Meinolf Karthaus · 1 shared paper, 2026 · strength 0.22
  4. Manfred Paul Lutz · 1 shared paper, 2026 · strength 0.22
  5. Dirk Waldschmidt · 1 shared paper, 2026 · strength 0.22
  6. Przemyslaw M. Bozko · 2 shared papers, 2014–2017 · strength 0.11
  7. Bence Sipos · 2 shared papers, 2014–2017 · strength 0.11
  8. Xi Chen · 1 shared paper, 2017 · strength 0.07
  9. Constantin Maier-Stocker · 1 shared paper, 2014 · strength 0.06
  10. Frank Kullmann · 1 shared paper, 2015 · strength 0.05
  11. Volker Kunzmann · 1 shared paper, 2015 · strength 0.05
  12. Arndt Vogel · 1 shared paper, 2015 · strength 0.05
  13. Christoph Springfeld · 1 shared paper, 2015 · strength 0.05
  14. Jens Thomas Siveke · 1 shared paper, 2015 · strength 0.05
  15. Helmut Oettle · 1 shared paper, 2015 · strength 0.05
  16. Hanno B. Riess · 1 shared paper, 2015 · strength 0.05
  17. Salah‐Eddin Al‐Batran · 1 shared paper, 2015 · strength 0.05
  18. Vindhya Palagani · 1 shared paper, 2014 · strength 0.04
  19. Nathalia A. Giese · 1 shared paper, 2014 · strength 0.04
  20. Bastian Schönemeier · 1 shared paper, 2016 · strength 0.04
  21. Tim Oliver Lankisch · 1 shared paper, 2016 · strength 0.04
  22. Florian Kühnel · 1 shared paper, 2016 · strength 0.04
  23. Jonas Rosendahl · 1 shared paper, 2016 · strength 0.04
  24. Hao Zhang · 1 shared paper, 2014 · strength 0.04
  25. Pankaj Jay Pasricha · 1 shared paper, 2014 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.